DRUG-TREATMENT OF EPILEPSY - A REVIEW

被引：0
作者：
ROSENBLOOM, D
UPTON, ARM
机构：
[1] CHEDOKE MCMASTER HOSP,MCMASTER DIV,DEPT PHARACEUT SERV,HAMILTON,ONTARIO,CANADA
[2] CHEDOKE MCMASTER HOSP,MCMASTER DIV,DEPT MED,HAMILTON,ONTARIO,CANADA
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 1983年 / 128卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：261 / 270
页数：10
相关论文
共 85 条
[41]   VALPROIC ACID AND ETHOSUXIMIDE INTERACTION [J].
MATTSON, RH ;
CRAMER, JA .
ANNALS OF NEUROLOGY, 1980, 7 (06) :583-584
[42]  
MEINARDI H, 1972, ANTIEPILEPTIC DRUGS, P487
[43]   METHODS OF ASSESSMENT OF ANTIEPILEPTIC DRUGS [J].
MILLIGAN, N ;
RICHENS, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (05) :443-456
[44]   EFFECT OF SINGLE DOSES OF SODIUM VALPROATE ON SERUM PHENYTOIN LEVELS AND PROTEIN-BINDING IN EPILEPTIC PATIENTS [J].
MONKS, A ;
RICHENS, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (01) :89-95
[45]  
Morselli P L, 1975, Adv Neurol, V11, P279
[46]   CLINICAL UTILITY OF 6 METHODS OF PREDICTING PHENYTOIN DOSES AND PLASMA-CONCENTRATIONS [J].
MURPHY, JE ;
BRUNI, J ;
STEWART, RB .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1981, 38 (03) :348-354
[47]  
NANDEDKAR AKN, 1980, THER DRUG MONIT, V2, P427
[48]   BIOAVAILABILITY OF PHENYTOIN - CLINICAL PHARMACOKINETIC AND THERAPEUTIC IMPLICATIONS [J].
NEUVONEN, PJ .
CLINICAL PHARMACOKINETICS, 1979, 4 (02) :91-103
[49]   METABOLIC CONVERSION OF PRIMIDONE (MYSOLINE) TO PHENOBARBITONE IN PATIENTS UNDER LONG-TERM TREATMENT - AN ATTEMPT TO ESTIMATE INDEPENDENT EFFECT OF PRIMIDONE [J].
OLESEN, OV ;
DAM, M .
ACTA NEUROLOGICA SCANDINAVICA, 1967, 43 (03) :348-+
[50]  
OLLERDAURELLA L, 1977, EPILEPSY, P69
123456789